1.Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y, Kato A, Nash RJ, Lee HS, Ryu KS: Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.). J Agric Food Chem 2001, 49(9):4208-4213.
2.Dugo P, Mondello L, Errante G, Zappia G, Dugo G: Identification of anthocyanins in berries by narrow-bore high-performance liquid chromatography with electrospray ionization detection. J Agric Food Chem 2001, 49(8):3987-3992.
3.Mitcheva M, Astroug H, Drenska D, Popov A, Kassarova M: Biochemical and morphological studies on the effects of anthocyans and vitamin E on carbon tetrachloride induced liver injury. Cell Mol Biol (Noisy-le-grand) 1993, 39(4):443-448.
4.Morse MA, Stoner GD: Cancer chemoprevention: principles and prospects. Carcinogenesis 1993, 14(9):1737-1746.
5.Middleton E, Jr., Kandaswami C, Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000, 52(4):673-751.
6.Tewari RK, Kumar P, Sharma PN: Antioxidant responses to enhanced generation of superoxide anion radical and hydrogen peroxide in the copper-stressed mulberry plants. Planta 2006, 223(6):1145-1153.
7.Nattapong S, Omboon L: A new source of whitening agent from a Thai Mulberry plant and its betulinic acid quantitation. Nat Prod Res 2008, 22(9):727-734.
8.Kim AJ, Park S: Mulberry extract supplements ameliorate the inflammation-related hematological parameters in carrageenan-induced arthritic rats. J Med Food 2006, 9(3):431-435.
9.Shih PH, Chan YC, Liao JW, Wang MF, Yen GC: Antioxidant and cognitive promotion effects of anthocyanin-rich mulberry (Morus atropurpurea L.) on senescence-accelerated mice and prevention of Alzheimer''s disease. J Nutr Biochem 2010, 21(7):598-605.
10.Huang HP, Shih YW, Chang YC, Hung CN, Wang CJ: Chemoinhibitory effect of mulberry anthocyanins on melanoma metastasis involved in the Ras/PI3K pathway. J Agric Food Chem 2008, 56(19):9286-9293.
11.Liu LK, Lee HJ, Shih YW, Chyau CC, Wang CJ: Mulberry anthocyanin extracts inhibit LDL oxidation and macrophage-derived foam cell formation induced by oxidative LDL. J Food Sci 2008, 73(6):H113-121.
12.Chen CC, Liu LK, Hsu JD, Huang HP, Y YM, Wang CJ: Mulberry extract inhibits the development of atherosclerosis in cholesterol-fed rabbits Food Chemistry 2005, 91(4):601-607
13.Liu LK, Chou FP, Chen YC, Chyau CC, Ho HH, Wang CJ: Effects of mulberry (Morus alba L.) extracts on lipid homeostasis in vitro and in vivo. J Agric Food Chem 2009, 57(16):7605-7611.
14.鄭雅方: 荷葉多酚活化p38 MAPK/FasL 致人類乳癌細胞MCF-7 凋亡作用. 中山醫學大學生化暨生物科技研究所碩士論文 200615.Medina I, Satue-Gracia MT, German JB, Frankel EN: Comparison of natural polyphenol antioxidants from extra virgin olive oil with synthetic antioxidants in tuna lipids during thermal oxidation. J Agric Food Chem 1999, 47(12):4873-4879.
16.Lopes GK, Schulman HM, Hermes-Lima M: Polyphenol tannic acid inhibits hydroxyl radical formation from Fenton reaction by complexing ferrous ions. Biochim Biophys Acta 1999, 1472(1-2):142-152.
17.Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998, 56(11):317-333.
18.Scalbert A, Williamson G: Dietary intake and bioavailability of polyphenols. J Nutr 2000, 130(8S Suppl):2073S-2085S.
19.Sakakibara H, Honda Y, Nakagawa S, Ashida H, Kanazawa K: Simultaneous determination of all polyphenols in vegetables, fruits, and teas. J Agric Food Chem 2003, 51(3):571-581.
20.Scalbert A, Morand C, Manach C, Remesy C: Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother 2002, 56(6):276-282.
21.Rice-Evans C: Flavonoid antioxidants. Curr Med Chem 2001, 8(7):797-807.
22.Fuhrman B, Aviram M: Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 2001, 12(1):41-48.
23.Kris-Etherton PM, Keen CL: Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr Opin Lipidol 2002, 13(1):41-49.
24.Herrmann K: Occurrence and content of hydroxycinnamic and hydroxybenzoic acid compounds in foods. Crit Rev Food Sci Nutr 1989, 28(4):315-347.
25.Ness AR, Powles JW: Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 1997, 26(1):1-13.
26.Radtke J, Linseisen J, Wolfram G: [Phenolic acid intake of adults in a Bavarian subgroup of the national food consumption survey]. Z Ernahrungswiss 1998, 37(2):190-197.
27.Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T: Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim Biophys Acta 1984, 792(1):92-97.
28.Fernandez MA, Saenz MT, Garcia MD: Anti-inflammatory activity in rats and mice of phenolic acids isolated from Scrophularia frutescens. J Pharm Pharmacol 1998, 50(10):1183-1186.
29.Gao SW, Chen ZJ: [Effects of sodium ferulate on platelet aggregation and platelet thromboxane A2 in patients with coronary heart disease]. Zhong Xi Yi Jie He Za Zhi 1988, 8(5):263-265, 259.
30.Huang MT, Smart RC, Wong CQ, Conney AH: Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988, 48(21):5941-5946.
31.Singh S, Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995, 270(42):24995-25000.
32.Laranjinha J, Vierira O, Almeida L, Madeira V: Inhibition of metmyoglobin/H2O2-dependent low density lipoprotein lipid peroxidation by naturally occurring phenolic acids. Biochem Pharmacol 1996, 51(4):395-402.
33.Reddy S, Aggarwal BB: Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 1994, 341(1):19-22.
34.Natarajan K, Singh S, Burke TR, Jr., Grunberger D, Aggarwal BB: Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 1996, 93(17):9090-9095.
35.Bito T, Roy S, Sen CK, Packer L: Pine bark extract pycnogenol downregulates IFN-gamma-induced adhesion of T cells to human keratinocytes by inhibiting inducible ICAM-1 expression. Free Radic Biol Med 2000, 28(2):219-227.
36.Duthie G, Crozier A: Plant-derived phenolic antioxidants. Curr Opin Lipidol 2000, 11(1):43-47.
37.Aguilera CM, Ramirez-Tortosa MC, Mesa MD, Gil A: [Protective effect of monounsaturated and polyunsaturated fatty acids on the development of cardiovascular disease]. Nutr Hosp 2001, 16(3):78-91.
38.Bub A, Watzl B, Blockhaus M, Briviba K, Liegibel U, Muller H, Pool-Zobel BL, Rechkemmer G: Fruit juice consumption modulates antioxidative status, immune status and DNA damage. J Nutr Biochem 2003, 14(2):90-98.
39.Yochum L, Kushi LH, Meyer K, Folsom AR: Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol 1999, 149(10):943-949.
40.Hertog MG, Feskens EJ, Kromhout D: Antioxidant flavonols and coronary heart disease risk. Lancet 1997, 349(9053):699.
41.Nigdikar SV, Williams NR, Griffin BA, Howard AN: Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr 1998, 68(2):258-265.
42.Kuntz S, Wenzel U, Daniel H: Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 1999, 38(3):133-142.
43.Wenzel U, Kuntz S, Brendel MD, Daniel H: Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000, 60(14):3823-3831.
44.Zhu M, Gong Y, Yang Z, Ge G, Han C, Chen J: Green tea and its major components ameliorate immune dysfunction in mice bearing Lewis lung carcinoma and treated with the carcinogen NNK. Nutr Cancer 1999, 35(1):64-72.
45.Chen PN, Chu SC, Chiou HL, Kuo WH, Chiang CL, Hsieh YS: Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Cancer Lett 2006, 235(2):248-259.
46.Zhang Y, Vareed SK, Nair MG: Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life Sci 2005, 76(13):1465-1472.
47.Olsson ME, Gustavsson KE, Andersson S, Nilsson A, Duan RD: Inhibition of cancer cell proliferation in vitro by fruit and berry extracts and correlations with antioxidant levels. J Agric Food Chem 2004, 52(24):7264-7271.
48.Zhao C, Giusti MM, Malik M, Moyer MP, Magnuson BA: Effects of commercial anthocyanin-rich extracts on colonic cancer and nontumorigenic colonic cell growth. J Agric Food Chem 2004, 52(20):6122-6128.
49.Chen YC, Liang YC, Lin-Shiau SY, Ho CT, Lin JK: Inhibition of TPA-induced protein kinase C and transcription activator protein-1 binding activities by theaflavin-3,3''-digallate from black tea in NIH3T3 cells. J Agric Food Chem 1999, 47(4):1416-1421.
50.Liang YC, Chen YC, Lin YL, Lin-Shiau SY, Ho CT, Lin JK: Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3''-digallate. Carcinogenesis 1999, 20(4):733-736.
51.Spencer JP, Abd-el-Mohsen MM, Rice-Evans C: Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch Biochem Biophys 2004, 423(1):148-161.
52.Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340(2):115-126.
53.Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL et al: The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996, 16(7):831-842.
54.Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK: Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci U S A 1999, 96(12):6920-6924.
55.Goldstein JL, Brown MS: The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977, 46:897-930.
56.Cybulsky MI, Gimbrone MA, Jr.: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251(4995):788-791.
57.Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD: The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 1998, 102(1):145-152.
58.Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL: P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000, 191(1):189-194.
59.Han KH, Han KO, Green SR, Quehenberger O: Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res 1999, 40(6):1053-1063.
60.Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2(2):275-281.
61.Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103(6):773-778.
62.Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394(6696):894-897.
63.Colles SM, Irwin KC, Chisolm GM: Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol. J Lipid Res 1996, 37(9):2018-2028.
64.Bennett MR, Macdonald K, Chan SW, Boyle JJ, Weissberg PL: Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res 1998, 82(6):704-712.
65.Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993, 69(5):377-381.
66.Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94(6):2493-2503.
67.Carmeliet P: Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest 2000, 105(11):1519-1520.
68.Vaux DL, Korsmeyer SJ: Cell death in development. Cell 1999, 96(2):245-254.
69.Bennett MR: Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999, 41(2):361-368.
70.Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320(14):915-924.
71.Yamada Y, Doi T, Hamakubo T, Kodama T: Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 1998, 54(7):628-640.
72.Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM: PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93(2):241-252.
73.Jha P, Flather M, Lonn E, Farkouh M, Yusuf S: The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med 1995, 123(11):860-872.
74.Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):154-160.
75.Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T et al: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386(6622):292-296.
76.Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000, 105(8):1049-1056.
77.Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
78.Cobb MH, Goldsmith EJ: How MAP kinases are regulated. J Biol Chem 1995, 270(25):14843-14846.
79.Lieu CH, Liu CC, Yu TH, Chen KD, Chang YN, Lai YK: Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ 1998, 9(9):767-776.
80.Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001, 410(6824):37-40.
81.Mohit AA, Martin JH, Miller CA: p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 1995, 14(1):67-78.
82.Ichijo H: From receptors to stress-activated MAP kinases. Oncogene 1999, 18(45):6087-6093.
83.Stadheim TA, Kucera GL: Extracellular signal-regulated kinase (ERK) activity is required for TPA-mediated inhibition of drug-induced apoptosis. Biochem Biophys Res Commun 1998, 245(1):266-271.
84.Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A, Hersberger M, Eriksson U, Eberli FR, Becher B et al: Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004, 306(5701):1558-1561.
85.Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL: A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006, 4(3):211-221.
86.Osman N, Ballinger ML, Dadlani HM, Getachew R, Burch ML, Little PJ: p38 MAP kinase mediated proteoglycan synthesis as a target for the prevention of atherosclerosis. Cardiovasc Hematol Disord Drug Targets 2008, 8(4):287-292.
87.F. See AK, H. Krum: p38 MAP kinase as a therapeutic target in cardiovascular disease Drug Discovery Today: Therapeutic Strategies 2004, 1(2):149-154.
88.Zhao M, Liu Y, Wang X, New L, Han J, Brunk UT: Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. APMIS 2002, 110(6):458-468.
89.Lei ZB, Zhang Z, Jing Q, Qin YW, Pei G, Cao BZ, Li XY: OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase. Cardiovasc Res 2002, 53(2):524-532.
90.Jin JO, Park HY, Xu Q, Park JI, Zvyagintseva T, Stonik VA, Kwak JY: Ligand of scavenger receptor class A indirectly induces maturation of human blood dendritic cells via production of tumor necrosis factor-alpha. Blood 2009, 113(23):5839-5847.
91.Tabata T, Mine S, Kawahara C, Okada Y, Tanaka Y: Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem Biophys Res Commun 2003, 305(2):380-385.
92.Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D et al: Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007, 100(10):1442-1451.
93.Eguchi A, Murakami A, Ohigashi H: Nobiletin, a citrus flavonoid, suppresses phorbol ester-induced expression of multiple scavenger receptor genes in THP-1 human monocytic cells. FEBS Lett 2006, 580(13):3321-3328.
94.Dubois M, Gilles K, Hamilton JK, Rebers PA, Smith F: A colorimetric method for the determination of sugars. Nature 1951, 168(4265):167.
95.Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34(9):1345-1353.
96.Reid VC, Mitchinson MJ, Skepper JN: Cytotoxicity of oxidized low-density lipoprotein to mouse peritoneal macrophages: an ultrastructural study. J Pathol 1993, 171(4):321-328.
97.Miura Y, Chiba T, Miura S, Tomita I, Umegaki K, Ikeda M, Tomita T: Green tea polyphenols (flavan 3-ols) prevent oxidative modification of low density lipoproteins: an ex vivo study in humans. J Nutr Biochem 2000, 11(4):216-222.
98.Yagi K, Komura S: Inhibitory effect of female hormones on lipid peroxidation. Biochem Int 1986, 13(6):1051-1055.
99.Ursini F, Maiorino M, Morazzoni P, Roveri A, Pifferi G: A novel antioxidant flavonoid (IdB 1031) affecting molecular mechanisms of cellular activation. Free Radic Biol Med 1994, 16(5):547-553.
100.Hsu HY, Twu YC: Tumor necrosis factor-alpha -mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage. J Biol Chem 2000, 275(52):41035-41048.
101.Chen JH, Tseng TH, Ho YC, Lin HH, Lin WL, Wang CJ: Gaseous nitrogen oxides stimulate cell cycle progression by retinoblastoma phosphorylation via activation of cyclins/Cdks [correction]. Toxicol Sci 2003, 76(1):83-90.
102.Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999, 13(22):2905-2927.
103.Kang JH, Kim JK, Park WH, Park KK, Lee TS, Magae J, Nakajima H, Kim CH, Chang YC: Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages. J Cell Biochem 2007, 102(2):506-514.
104.Liu WH, Chen XM, Fu B: Thrombin stimulates MMP-9 mRNA expression through AP-1 pathway in human mesangial cells. Acta Pharmacol Sin 2000, 21(7):641-645.
105.Li MH, Jang JH, Surh YJ: Nitric oxide induces apoptosis via AP-1-driven upregulation of COX-2 in rat pheochromocytoma cells. Free Radic Biol Med 2005, 39(7):890-899.
106.Kriehuber E, Bauer W, Charbonnier AS, Winter D, Amatschek S, Tamandl D, Schweifer N, Stingl G, Maurer D: Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood 2005, 106(1):175-183.
107.Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26(4):239-257.
108.Van Cruchten S, Van Den Broeck W: Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002, 31(4):214-223.
109.Evan G, Littlewood T: A matter of life and cell death. Science 1998, 281(5381):1317-1322.
110.Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S, Fried VA, Minamoto T, Alarcon-Vargas D, Pincus MR et al: Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001, 21(8):2743-2754.
111.Hugon J, Esclaire F, Terro F, Yardin C: [Apoptosis and Alzheimer disease. Contribution of cellular and transgenic models]. Rev Neurol (Paris) 2000, 156(2):123-125.
112.Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998, 391(6662):96-99.
113.Nagata S: Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci 1994, 345(1313):281-287.
114.Rodriguez J, Lazebnik Y: Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 1999, 13(24):3179-3184.
115.Nagata S: Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 1996, 16:87-103.
116.Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene 2003, 22(56):9030-9040.
117.Kawahara A, Kobayashi T, Nagata S: Inhibition of Fas-induced apoptosis by Bcl-2. Oncogene 1998, 17(20):2549-2554.
118.Nagata M, Nakauchi H, Nakayama K, Loh D, Watanabe T: Apoptosis during an early stage of nephrogenesis induces renal hypoplasia in bcl-2-deficient mice. Am J Pathol 1996, 148(5):1601-1611.
119.Nagata S, Golstein P: The Fas death factor. Science 1995, 267(5203):1449-1456.
120.Thompson EB: The many roles of c-Myc in apoptosis. Annu Rev Physiol 1998, 60:575-600.
121.Ayer DE, Kretzner L, Eisenman RN: Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993, 72(2):211-222.
122.Packham G, Cleveland JL: The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol Immunol 1995, 194:283-290.
123.Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K: Function of the c-Myc oncogenic transcription factor. Exp Cell Res 1999, 253(1):63-77.
124.Facchini LM, Penn LZ: The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998, 12(9):633-651.
125.Ben-Porath I, Yanuka O, Benvenisty N: The tmp gene, encoding a membrane protein, is a c-Myc target with a tumorigenic activity. Mol Cell Biol 1999, 19(5):3529-3539.
126.Nilsson JA, Cleveland JL: Myc pathways provoking cell suicide and cancer. Oncogene 2003, 22(56):9007-9021.
127.Adams JM, Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001, 26(1):61-66.
128.Strasser A, O''Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem 2000, 69:217-245.
129.Antonsson B, Montessuit S, Sanchez B, Martinou JC: Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001, 276(15):11615-11623.
130.Huang DC, Strasser A: BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000, 103(6):839-842.
131.Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003, 39(11):615-647.
132.Cory S, Huang DC, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22(53):8590-8607.
133.Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997, 90(3):405-413.
134.Wilson KP, Black JA, Thomson JA, Kim EE, Griffith JP, Navia MA, Murcko MA, Chambers SP, Aldape RA, Raybuck SA et al: Structure and mechanism of interleukin-1 beta converting enzyme. Nature 1994, 370(6487):270-275.
135.Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998, 281(5381):1312-1316.
136.Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998, 273(50):33533-33539.
137.Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 1996, 271(28):16443-16446.
138.Wolf BB, Schuler M, Echeverri F, Green DR: Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999, 274(43):30651-30656.
139.Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391(6662):43-50.
140.Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J et al: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992, 356(6372):768-774.
141.Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene 2003, 22(53):8543-8567.
142.Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298(5600):1911-1912.
143.Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270(5240):1326-1331.
144.Zhu Y, Mao XO, Sun Y, Xia Z, Greenberg DA: p38 Mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J Biol Chem 2002, 277(25):22909-22914.
145.Orlov SN, Dam TV, Tremblay J, Hamet P: Apoptosis in vascular smooth muscle cells: role of cell shrinkage. Biochem Biophys Res Commun 1996, 221(3):708-715.
146.Walsh K, Isner JM: Apoptosis in inflammatory-fibroproliferative disorders of the vessel wall. Cardiovasc Res 2000, 45(3):756-765.
147.Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim K: Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991, 17(2):433-439.
148.Clowes AW, Schwartz SM: Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985, 56(1):139-145.
149.Pollman MJ, Yamada T, Horiuchi M, Gibbons GH: Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996, 79(4):748-756.
150.Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K: Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci U S A 1998, 95(3):1213-1217.
151.Lisi DM: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997, 337(26):1919.
152.Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S et al: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997, 30(4):855-862.
153.Pollman MJ, Hall JL, Gibbons GH: Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 1999, 84(1):113-121.
154.Bennett MR, Evan GI, Schwartz SM: Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Circ Res 1995, 77(2):266-273.
155.Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988, 48(17):4827-4833.
156.Peng CH, Huang CN, Hsu SP, Wang CJ: Penta-acetyl geniposide induce apoptosis in C6 glioma cells by modulating the activation of neutral sphingomyelinase-induced p75 nerve growth factor receptor and protein kinase Cdelta pathway. Mol Pharmacol 2006, 70(3):997-1004.
157.Lin HH, Huang HP, Huang CC, Chen JH, Wang CJ: Hibiscus polyphenol-rich extract induces apoptosis in human gastric carcinoma cells via p53 phosphorylation and p38 MAPK/FasL cascade pathway. Mol Carcinog 2005, 43(2):86-99.
158.Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S: Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 2004, 24(12):5565-5576.
159.Jacob T, Ascher E, Alapat D, Olevskaia Y, Hingorani A: Activation of p38MAPK signaling cascade in a VSMC injury model: role of p38MAPK inhibitors in limiting VSMC proliferation. Eur J Vasc Endovasc Surg 2005, 29(5):470-478.
160.Lee B, Moon SK: Ras/ERK signaling pathway mediates activation of the p21WAF1 gene promoter in vascular smooth muscle cells by platelet-derived growth factor. Arch Biochem Biophys 2005, 443(1-2):113-119.
161.Tanski WJ, Nicholl SM, Kim D, Fegley AJ, Roztocil E, Davies MG: Sphingosine-1-phosphate-induced smooth muscle cell migration involves the mammalian target of rapamycin. J Vasc Surg 2005, 41(1):91-98.
162.Nath P, Eynott P, Leung SY, Adcock IM, Bennett BL, Chung KF: Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur J Pharmacol 2005, 506(3):273-283.
163.Kashiwakura Y, Watanabe M, Kusumi N, Sumiyoshi K, Nasu Y, Yamada H, Sawamura T, Kumon H, Takei K, Daida H: Dynamin-2 regulates oxidized low-density lipoprotein-induced apoptosis of vascular smooth muscle cell. Circulation 2004, 110(21):3329-3334.
164.Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996, 87(4):629-638.
165.Jin S, Zhuo Y, Guo W, Field J: p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 2005, 280(26):24698-24705.
166.Zhong J, Troppmair J, Rapp UR: Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 2001, 20(35):4807-4816.
167.Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K, Janicke RU: Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ 2009, 16(6):869-878.
168.Galluzzi L, Morselli E, Kepp O, Tajeddine N, Kroemer G: Targeting p53 to mitochondria for cancer therapy. Cell Cycle 2008, 7(13):1949-1955.
169.Marchenko ND, Zaika A, Moll UM: Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000, 275(21):16202-16212.
170.Murphy ME, Leu JI, George DL: p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 2004, 3(7):836-839.
171.Leu JI, George DL: Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev 2007, 21(23):3095-3109.
172.Jiang P, Du W, Heese K, Wu M: The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol 2006, 26(23):9071-9082.
173.Park BS, Song YS, Yee SB, Lee BG, Seo SY, Park YC, Kim JM, Kim HM, Yoo YH: Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Apoptosis 2005, 10(1):193-200.
174.Chulu JL, Lee LH, Lee YC, Liao SH, Lin FL, Shih WL, Liu HJ: Apoptosis induction by avian reovirus through p53 and mitochondria-mediated pathway. Biochem Biophys Res Commun 2007, 356(3):529-535.
175.Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, Waterhouse NJ, Green DR: p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 2003, 10(4):451-460.
176.Deng Y, Wu X: Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci U S A 2000, 97(22):12050-12055.
177.Lee SK, Kim YC, Song SB, Kim YS: Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun 2010, 391(4):1592-1597.
178.Yang H, Li TW, Ko KS, Xia M, Lu SC: Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Hepatology 2009, 49(3):860-870.
179.Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV: A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285(5434):1733-1737.
180.Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R et al: Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006, 2(9):474-479.
181.Marchenko ND, Wolff S, Erster S, Becker K, Moll UM: Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 2007, 26(4):923-934.
182.Shah MA, Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001, 7(8):2168-2181.
183.Wang CJ, Hsieh YJ, Chu CY, Lin YL, Tseng TH: Inhibition of cell cycle progression in human leukemia HL-60 cells by esculetin. Cancer Lett 2002, 183(2):163-168.
184.Koepp DM, Harper JW, Elledge SJ: How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999, 97(4):431-434.
185.Hunter T, Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994, 79(4):573-582.
186.Hunter T, Pines J: Cyclins and cancer. Cell 1991, 66(6):1071-1074.
187.Halaban R: Melanoma cell autonomous growth: the Rb/E2F pathway. Cancer Metastasis Rev 1999, 18(3):333-343.
188.Laskey RA, Fairman MP, Blow JJ: S phase of the cell cycle. Science 1989, 246(4930):609-614.
189.Hao XF, Alphey L, Bandara LR, Lam EW, Glover D, La Thangue NB: Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster. J Cell Sci 1995, 108 ( Pt 9):2945-2954.
190.Tyson JJ, Novak B, Odell GM, Chen K, Thron CD: Chemical kinetic theory: understanding cell-cycle regulation. Trends Biochem Sci 1996, 21(3):89-96.
191.McGill CJ, Brooks G: Cell cycle control mechanisms and their role in cardiac growth. Cardiovasc Res 1995, 30(4):557-569.
192.Li JM, Brooks G: Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Eur Heart J 1999, 20(6):406-420.
193.Martinez AM, Afshar M, Martin F, Cavadore JC, Labbe JC, Doree M: Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity. EMBO J 1997, 16(2):343-354.
194.Andersen G, Busso D, Poterszman A, Hwang JR, Wurtz JM, Ripp R, Thierry JC, Egly JM, Moras D: The structure of cyclin H: common mode of kinase activation and specific features. EMBO J 1997, 16(5):958-967.
195.Wolgemuth DJ, Lele KM, Jobanputra V, Salazar G: The A-type cyclins and the meiotic cell cycle in mammalian male germ cells. Int J Androl 2004, 27(4):192-199.
196.el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75(4):817-825.
197.Funk JO, Galloway DA: Inhibiting CDK inhibitors: new lessons from DNA tumor viruses. Trends Biochem Sci 1998, 23(9):337-341.
198.Sherr CJ: Cancer cell cycles. Science 1996, 274(5293):1672-1677.
199.Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992, 258(5081):424-429.
200.van der Sman J, Thomas NS, Lam EW: Modulation of E2F complexes during G0 to S phase transition in human primary B-lymphocytes. J Biol Chem 1999, 274(17):12009-12016.
201.Beijersbergen RL, Kerkhoven RM, Zhu L, Carlee L, Voorhoeve PM, Bernards R: E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 1994, 8(22):2680-2690.
202.Ginsberg D, Vairo G, Chittenden T, Xiao ZX, Xu G, Wydner KL, DeCaprio JA, Lawrence JB, Livingston DM: E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev 1994, 8(22):2665-2679.
203.Lindeman GJ, Gaubatz S, Livingston DM, Ginsberg D: The subcellular localization of E2F-4 is cell-cycle dependent. Proc Natl Acad Sci U S A 1997, 94(10):5095-5100.
204.Chen J, Lin J, Levine AJ: Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1995, 1(2):142-152.
205.Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A et al: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004, 24(13):5835-5843.
206.Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264(5157):436-440.
207.Shibata K, Tanaka S, Shiraishi T, Kitano S, Mori M: G-protein gamma 7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Res 1999, 59(5):1096-1101.
208.Wang Z, Van Tuyle G, Conrad D, Fisher PB, Dent P, Grant S: Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Cancer Res 1999, 59(6):1259-1267.
209.Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M: P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines. J Clin Invest 1993, 91(5):2111-2117.
210.Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78(1):67-74.
211.Lorenzoni R, Gistri R, Cecchi F, Olivotto I, Chiriatti G, Elliott P, McKenna WJ, Camici PG: Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. Eur Heart J 1997, 18(12):1946-1950.
212.Giaid A: Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998, 114(3 Suppl):208S-212S.
213.Warren JB, Brady AJ, Taylor GW: Vascular smooth muscle influences the release of endothelium-derived relaxing factor. Proc Biol Sci 1990, 241(1301):127-131.
214.Raij L: Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998, 31(1 Pt 2):189-193.
215.Fabricius M, Rubin I, Bundgaard M, Lauritzen M: NOS activity in brain and endothelium: relation to hypercapnic rise of cerebral blood flow in rats. Am J Physiol 1996, 271(5 Pt 2):H2035-2044.
216.Boulanger CM, Heymes C, Benessiano J, Geske RS, Levy BI, Vanhoutte PM: Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res 1998, 83(12):1271-1278.
217.殷麒超: 超氧陰離子對血管平滑肌之一氧化氮生物活性的影響. 國立中正大學化學工程所 2007.
218.Kibbe M, Billiar T, Tzeng E: Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999, 43(3):650-657.
219.Hecker M, Cattaruzza M, Wagner AH: Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol 1999, 32(1):9-16.
220.Yang Z, Wang S: [Relationship between nitric oxide synthase, endothelin and the initiation of hypertension and atherosclerosis]. Hua Xi Yi Ke Da Xue Xue Bao 1998, 29(2):160-164.
221.Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF: Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998, 97(25):2494-2498.
222.Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99(9):1141-1146.
223.Dulak J, Tomala K, Loboda A, Jozkowicz A: Nitric oxide-dependent synthesis of vascular endothelial growth factor is impaired by high glucose. Life Sci 2004, 75(21):2573-2586.
224.Hardie DG, Scott JW, Pan DA, Hudson ER: Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546(1):113-120.
225.Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG: Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 1996, 271(44):27879-27887.
226.Davies SP, Helps NR, Cohen PT, Hardie DG: 5''-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 1995, 377(3):421-425.
227.Rutter GA, Da Silva Xavier G, Leclerc I: Roles of 5''-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 2003, 375(Pt 1):1-16.
228.Corton JM, Gillespie JG, Hawley SA, Hardie DG: 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995, 229(2):558-565.
229.Aschenbach WG, Sakamoto K, Goodyear LJ: 5'' adenosine monophosphate-activated protein kinase, metabolism and exercise. Sports Med 2004, 34(2):91-103.
230.Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100(3):328-341.
231.Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005, 102(23):8204-8209.
232.Hoyer-Hansen M, Jaattela M: AMP-activated protein kinase: a universal regulator of autophagy? Autophagy 2007, 3(4):381-383.
233.Brito PM, Devillard R, Negre-Salvayre A, Almeida LM, Dinis TC, Salvayre R, Auge N: Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis 2009, 205(1):126-134.
234.Ratnovsky A, Mellema M, An SS, Fredberg JJ, Shore SA: Airway smooth muscle proliferation and mechanics: effects of AMP kinase agonists. Mol Cell Biomech 2007, 4(3):143-157.
235.Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y: AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004, 110(4):444-451.
236.Rubin LJ, Magliola L, Feng X, Jones AW, Hale CC: Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol 2005, 98(1):296-306.
237.Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, Kemp BE: AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999, 443(3):285-289.
238.Nagata D, Mogi M, Walsh K: AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 2003, 278(33):31000-31006.
239.Almeida A, Cidad P, Delgado-Esteban M, Fernandez E, Garcia-Nogales P, Bolanos JP: Inhibition of mitochondrial respiration by nitric oxide: its role in glucose metabolism and neuroprotection. J Neurosci Res 2005, 79(1-2):166-171.
240.Dixit M, Bess E, Fisslthaler B, Hartel FV, Noll T, Busse R, Fleming I: Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc Res 2008, 77(1):160-168.
241.Fisslthaler B, Fleming I, Keseru B, Walsh K, Busse R: Fluid shear stress and NO decrease the activity of the hydroxy-methylglutaryl coenzyme A reductase in endothelial cells via the AMP-activated protein kinase and FoxO1. Circ Res 2007, 100(2):e12-21.
242.Nagata D, Hirata Y: The role of AMP-activated protein kinase in the cardiovascular system. Hypertens Res, 33(1):22-28.
243.Stuehr DJ, Nathan CF: Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989, 169(5):1543-1555.
244.Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8(10):774-785.
245.Wever RM, Luscher TF, Cosentino F, Rabelink TJ: Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998, 97(1):108-112.
246.Albina JE, Reichner JS: Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. Cancer Metastasis Rev 1998, 17(1):39-53.
247.Chae IH, Park KW, Kim HS, Oh BH: Nitric oxide-induced apoptosis is mediated by Bax/Bcl-2 gene expression, transition of cytochrome c, and activation of caspase-3 in rat vascular smooth muscle cells. Clin Chim Acta 2004, 341(1-2):83-91.
248.Pilane CM, Labelle EF: Nitric oxide stimulated vascular smooth muscle cells undergo apoptosis induced in part by arachidonic acid derived eicosanoids. J Cell Physiol 2005, 204(2):423-427.
249.Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M: Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Invest 2004, 34(10):664-673.
250.Haider A, Lee I, Grabarek J, Darzynkiewicz Z, Ferreri NR: Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation. Circulation 2003, 108(8):1015-1021.
251.Kibbe MR, Li J, Nie S, Watkins SC, Lizonova A, Kovesdi I, Simmons RL, Billiar TR, Tzeng E: Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg 2000, 31(6):1214-1228.
252.Chamley JH, Groschel-Stewart U, Campbell GR, Burnstock G: Distinction between smooth muscle, fibroblasts and endothelial cells in culture by the use of fluoresceinated antibodies against smooth muscle actin. Cell Tissue Res 1977, 177(4):445-457.
253.Chamley-Campbell JH, Campbell GR, Ross R: Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J Cell Biol 1981, 89(2):379-383.
254.Schwartz SM, Campbell GR, Campbell JH: Replication of smooth muscle cells in vascular disease. Circ Res 1986, 58(4):427-444.
255.Luscher TF: Endothelium in the control of vascular tone and growth: role of local mediators and mechanical forces. Blood Press Suppl 1994, 1:18-22.
256.Raines EW: The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol 2000, 81(3):173-182.
257.Fager G, Camejo G, Olsson U, Ostergren-Lunden G, Bondjers G: Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. II. The platelet-derived growth factor A-chain contains a sequence that specifically binds heparin. In Vitro Cell Dev Biol 1992, 28A(3 Pt 1):176-180.
258.Yamamoto M, Yamamoto K, Noumura T: Type I collagen promotes modulation of cultured rabbit arterial smooth muscle cells from a contractile to a synthetic phenotype. Exp Cell Res 1993, 204(1):121-129.
259.Khan R, Agrotis A, Bobik A: Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc Res 2007, 74(2):223-234.
260.Fox GL, Rebay I, Hynes RO: Expression of DFak56, a Drosophila homolog of vertebrate focal adhesion kinase, supports a role in cell migration in vivo. Proc Natl Acad Sci U S A 1999, 96(26):14978-14983.
261.Schaller MD: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001, 1540(1):1-21.
262.Schaller MD, Parsons JT: Focal adhesion kinase and associated proteins. Curr Opin Cell Biol 1994, 6(5):705-710.
263.Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377(6549):539-544.
264.Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA: CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998, 140(4):961-972.
265.Campbell M, Trimble ER: Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII. Circ Res 2005, 96(2):197-206.
266.Van Aelst L, D''Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev 1997, 11(18):2295-2322.
267.Lim L, Manser E, Leung T, Hall C: Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. Eur J Biochem 1996, 242(2):171-185.
268.Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: a conserved switch for diverse cell functions. Nature 1990, 348(6297):125-132.
269.Bokoch GM, Der CJ: Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J 1993, 7(9):750-759.
270.Hall A: Ras-related proteins. Curr Opin Cell Biol 1993, 5(2):265-268.
271.Downward J: The ras superfamily of small GTP-binding proteins. Trends Biochem Sci 1990, 15(12):469-472.
272.Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991, 349(6305):117-127.
273.Sigal IS, Gibbs JB, D''Alonzo JS, Scolnick EM: Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc Natl Acad Sci U S A 1986, 83(13):4725-4729.
274.Adari H, Lowy DR, Willumsen BM, Der CJ, McCormick F: Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 1988, 240(4851):518-521.
275.Khwaja A: Akt is more than just a Bad kinase. Nature 1999, 401(6748):33-34.
276.Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997, 275(5306):1649-1652.
277.Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401(6748):86-90.
278.Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401(6748):82-85.
279.Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS, Jr.: Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997, 278(5344):1812-1815.
280.Chien KR, Hoshijima M: Unravelling Ras signals in cardiovascular disease. Nat Cell Biol 2004, 6(9):807-808.
281.Burridge K, Wennerberg K: Rho and Rac take center stage. Cell 2004, 116(2):167-179.
282.Hall A: Rho GTPases and the actin cytoskeleton. Science 1998, 279(5350):509-514.
283.Kaverina I, Krylyshkina O, Small JV: Regulation of substrate adhesion dynamics during cell motility. Int J Biochem Cell Biol 2002, 34(7):746-761.
284.Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K: Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997, 275(5304):1308-1311.
285.Seasholtz TM, Majumdar M, Kaplan DD, Brown JH: Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999, 84(10):1186-1193.
286.Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000, 275(24):17974-17978.
287.Du W, Prendergast GC: Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999, 59(21):5492-5496.
288.Fritz G, Kaina B, Aktories K: The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem 1995, 270(42):25172-25177.
289.Jahner D, Hunter T: The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts. Mol Cell Biol 1991, 11(7):3682-3690.
290.Cox AD, Der CJ: Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002, 1(6):599-606.
291.Barbacid M: ras genes. Annu Rev Biochem 1987, 56:779-827.
292.Jiang K, Delarue FL, Sebti SM: EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 2004, 23(5):1136-1145.
293.Kapeller R, Prasad KV, Janssen O, Hou W, Schaffhausen BS, Rudd CE, Cantley LC: Identification of two SH3-binding motifs in the regulatory subunit of phosphatidylinositol 3-kinase. J Biol Chem 1994, 269(3):1927-1933.
294.Welham MJ, Dechert U, Leslie KB, Jirik F, Schrader JW: Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 with Grb2 and phosphatidylinositol 3''-kinase. J Biol Chem 1994, 269(38):23764-23768.
295.Leevers SJ, Vanhaesebroeck B, Waterfield MD: Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999, 11(2):219-225.
296.Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, Krymskaya VP: PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002, 283(2):L354-363.
297.Isenovic ER, Kedees MH, Tepavcevic S, Milosavljevic T, Koricanac G, Trpkovic A, Marche P: Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation. Cardiovasc Hematol Disord Drug Targets 2009, 9(3):172-180.
298.Yang GY, Yao JS, Huey M, Hashimoto T, Young WL: Participation of PI3K and ERK1/2 pathways are required for human brain vascular smooth muscle cell migration. Neurochem Int 2004, 44(6):441-446.
299.Zhong H, May MJ, Jimi E, Ghosh S: The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002, 9(3):625-636.
300.Ghosh G, van Duyne G, Ghosh S, Sigler PB: Structure of NF-kappa B p50 homodimer bound to a kappa B site. Nature 1995, 373(6512):303-310.
301.Montaner S, Perona R, Saniger L, Lacal JC: Activation of serum response factor by RhoA is mediated by the nuclear factor-kappaB and C/EBP transcription factors. J Biol Chem 1999, 274(13):8506-8515.
302.Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107(3):241-246.
303.Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC: Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997, 11(4):463-475.
304.De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA: The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000, 20(11):E83-88.
305.Nagase H, Woessner JF, Jr.: Matrix metalloproteinases. J Biol Chem 1999, 274(31):21491-21494.
306.Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997, 74(2):111-122.
307.Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92(8):827-839.
308.Palanki MS: Inhibitors of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 2002, 9(2):219-227.
309.Yoshida M, Korfhagen TR, Whitsett JA: Surfactant protein D regulates NF-kappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J Immunol 2001, 166(12):7514-7519.
310.Aljada A, Ghanim H, Mohanty P, Hofmeyer D, Tripathy D, Dandona P: Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). J Clin Endocrinol Metab 2001, 86(12):5988-5991.
311.Qin H, Sun Y, Benveniste EN: The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999, 274(41):29130-29137.
312.Huang S, Bucana CD, Van Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002, 21(16):2504-2512.
313.Jean D, Bar-Eli M: Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy. Crit Rev Immunol 2001, 21(1-3):275-286.
314.Pan MR, Hung WC: Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 2002, 277(36):32775-32780.
315.Welch DR, Sakamaki T, Pioquinto R, Leonard TO, Goldberg SF, Hon Q, Erikson RL, Rieber M, Rieber MS, Hicks DJ et al: Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res 2000, 60(6):1552-1556.
316.Kubiatowski T, Jang T, Lachyankar MB, Salmonsen R, Nabi RR, Quesenberry PJ, Litofsky NS, Ross AH, Recht LD: Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 2001, 95(3):480-488.
317.Nagase H: Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res 1998, 8(3):179-186.
318.Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
319.Casey PJ, Thissen JA, Moomaw JF: Enzymatic modification of proteins with a geranylgeranyl isoprenoid. Proc Natl Acad Sci U S A 1991, 88(19):8631-8635.
320.Seabra MC, Goldstein JL, Sudhof TC, Brown MS: Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys. J Biol Chem 1992, 267(20):14497-14503.
321.Yau L, Litchie B, Thomas S, Storie B, Yurkova N, Zahradka P: Endogenous mono-ADP-ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N-dependent induction of c-fos expression. Eur J Biochem 2003, 270(1):101-110.
322.Cheng XW, Kuzuya M, Nakamura K, Liu Z, Di Q, Hasegawa J, Iwata M, Murohara T, Yokota M, Iguchi A: Mechanisms of the inhibitory effect of epigallocatechin-3-gallate on cultured human vascular smooth muscle cell invasion. Arterioscler Thromb Vasc Biol 2005, 25(9):1864-1870.
323.Chen PN, Hsieh YS, Chiou HL, Chu SC: Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 2005, 156(2-3):141-150.
324.Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R: Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 2004, 24(3):591-608.
325.Hommelberg PP, Plat J, Langen RC, Schols AM, Mensink RP: Fatty acid-induced NF-kappaB activation and insulin resistance in skeletal muscle are chain length dependent. Am J Physiol Endocrinol Metab 2009, 296(1):E114-120.
326.陳書郡: 桑葉多酚萃取物減少肝臟脂肪堆積之作用. 中山醫學大學生化暨生物科技研究所碩士論文 2009.327.Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y: Dislodgment and accelerated degradation of Ras. Biochemistry 1998, 37(5):1306-1314.
328.Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G et al: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1995, 1(6):541-545.
329.Wang H, Liu B, Fu M, Zeng C: [Transcriptional expression of oncogenes and Rb antioncogene in experimental atherosclerotic lesions]. Hua Xi Yi Ke Da Xue Xue Bao 1996, 27(2):117-121.
330.Yang CM, Chiu CT, Wang CC, Chien CS, Hsiao LD, Lin CC, Tu MT, Pan SL: Activation of mitogen-activated protein kinase by oxidized low-density lipoprotein in canine cultured vascular smooth muscle cells. Cell Signal 2000, 12(4):205-214.
331.Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP et al: Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 2004, 6(9):872-883.
332.Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
333.Hayflick L: The Limited in Vitro Lifetime of Human Diploid Cell Strains. Exp Cell Res 1965, 37:614-636.
334.Hadshiew IM, Eller MS, Gilchrest BA: Skin aging and photoaging: the role of DNA damage and repair. Am J Contact Dermat 2000, 11(1):19-25.
335.Oshimura M, Barrett JC: Multiple pathways to cellular senescence: role of telomerase repressors. Eur J Cancer 1997, 33(5):710-715.
336.Carman TA, Afshari CA, Barrett JC: Cellular senescence in telomerase-expressing Syrian hamster embryo cells. Exp Cell Res 1998, 244(1):33-42.
337.Kipling D: Telomeres, replicative senescence and human ageing. Maturitas 2001, 38(1):25-37; discussion 37-28.
338.Campisi J: The biology of replicative senescence. Eur J Cancer 1997, 33(5):703-709.
339.Weilbaecher RG, Lundblad V: Assembly and regulation of telomerase. Curr Opin Chem Biol 1999, 3(5):573-577.
340.Stein GH, Dulic V: Molecular mechanisms for the senescent cell cycle arrest. J Investig Dermatol Symp Proc 1998, 3(1):14-18.
341.Granger MP, Wright WE, Shay JW: Telomerase in cancer and aging. Crit Rev Oncol Hematol 2002, 41(1):29-40.
342.Henderson S, Allsopp R, Spector D, Wang SS, Harley C: In situ analysis of changes in telomere size during replicative aging and cell transformation. J Cell Biol 1996, 134(1):1-12.
343.Patterson H: Approaches to proto-oncogene and tumour suppressor gene identification. Eur J Cancer 1992, 28(1):258-263.
344.Foreman KE, Tang J: Molecular mechanisms of replicative senescence in endothelial cells. Exp Gerontol 2003, 38(11-12):1251-1257.
345.Blander G, de Oliveira RM, Conboy CM, Haigis M, Guarente L: Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem 2003, 278(40):38966-38969.
346.Brown JP, Wei W, Sedivy JM: Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277(5327):831-834.
347.Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92(20):9363-9367.
348.Krishna DR, Sperker B, Fritz P, Klotz U: Does pH 6 beta-galactosidase activity indicate cell senescence? Mech Ageing Dev 1999, 109(2):113-123.
349.Gorenne I, Kavurma M, Scott S, Bennett M: Vascular smooth muscle cell senescence in atherosclerosis. Cardiovasc Res 2006, 72(1):9-17.
350.Bonin LR, Madden K, Shera K, Ihle J, Matthews C, Aziz S, Perez-Reyes N, McDougall JK, Conroy SC: Generation and characterization of human smooth muscle cell lines derived from atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1999, 19(3):575-587.
351.Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H, Komuro I: Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation 2003, 108(18):2264-2269.
352.Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, Goddard M, Bennett M: Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 2006, 99(2):156-164.
353.Min LJ, Mogi M, Tamura K, Iwanami J, Sakata A, Fujita T, Tsukuda K, Jing F, Iwai M, Horiuchi M: Angiotensin II type 1 receptor-associated protein prevents vascular smooth muscle cell senescence via inactivation of calcineurin/nuclear factor of activated T cells pathway. J Mol Cell Cardiol 2009, 47(6):798-809.
354.Mahmoudi M, Gorenne I, Mercer J, Figg N, Littlewood T, Bennett M: Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ Res 2008, 103(7):717-725.
355.Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Shroff R, Skepper J, Shanahan CM: Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010, 121(20):2200-2210.